"A solid ontology-based analysis with a rigorous formal mapping for correctness" is one of the ten reasons why the HL7 standard Fast Healthcare Interoperability Resources (FHIR) is advertised to be better than other standards for EHR interoperability. In this paper, we aim at contributing to this formal analysis by proposing an RDF representation of a subset of FHIR resources based on a highly constrained top-level ontology and guided by the use of a set of Content Ontology Design Patterns (Content ODPs) for representing clinical information. We exemplify this by reinterpreting FHIR medication resources. Although a manual task now, we foresee a possible automatic translation by using RDF shapes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Web application using machine learning to predict cardiovascular disease and hypertension in mine workers.
Sci Rep
December 2024
Department of Applied Mathematics, Faculty of Mathematical Science, Ferdowsi University of Mashhad, Mashhad, Iran.
This study presents a web application for predicting cardiovascular disease (CVD) and hypertension (HTN) among mine workers using machine learning (ML) techniques. The dataset, collected from 699 participants at the Gol-Gohar mine in Iran between 2016 and 2020, includes demographic, occupational, lifestyle, and medical information. After preprocessing and feature engineering, the Random Forest algorithm was identified as the best-performing model, achieving 99% accuracy for HTN prediction and 97% for CVD, outperforming other algorithms such as Logistic Regression and Support Vector Machines.
View Article and Find Full Text PDFStudy of the litter in the urban environment as primary and secondary microplastics sources.
Sci Rep
December 2024
Environmental Technologies Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Microplastic is one of the most important environmental challenges of recent decades. Although the abundance of microplastics in water sources and water bodies such as the marine were investigated in many studies, knowing the sources of microplastics requires more studies. In this study, litter was investigated as one of the challenges of urban management and the sources of primary microplastic and secondary microplastic in the urban environment.
View Article and Find Full Text PDFStructure-function analysis of carrier protein-dependent 2-sulfamoylacetyl transferase in the biosynthesis of altemicidin.
Nat Commun
December 2024
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
The general control non-repressible 5 (GCN5)-related N-acetyltransferase (GNAT) SbzI, in the biosynthesis of the sulfonamide antibiotic altemicidin, catalyzes the transfer of the 2-sulfamoylacetyl (2-SA) moiety onto 6-azatetrahydroindane dinucleotide. While most GNAT superfamily utilize acyl-coenzyme A (acyl-CoA) as substrates, SbzI recognizes a carrier-protein (CP)-tethered 2-SA substrate. Moreover, SbzI is the only naturally occurring enzyme that catalyzes the direct incorporation of sulfonamide, a valuable pharmacophore in medicinal chemistry.
View Article and Find Full Text PDFSuccessful Orthopaedic Surgeries With World Federation of Haemophilia Humanitarian Aid Program in Resource-Limited Settings.
Haemophilia
December 2024
Haemostasis and Thrombosis, Manchester Royal Infirmary, MAHSC, University of Manchester, Manchester, UK.
Low-Dose Emicizumab Versus Low-/Intermediate-Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype.
Haemophilia
December 2024
Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: Subcutaneous emicizumab, a factor VIII (FVIII)-mimicking bispecific monoclonal antibody, can effectively prevent bleeds in haemophilia A (HA) patients with/without inhibitors; however, its standard-dose regimens are financially burdensome. Low-dose emicizumab prophylaxis may alternatively be applied to noninhibitor HA patients in resource-limited settings.
Methods: During 2023, Thai patients with noninhibitor severe HA or moderate HA with severe bleeding phenotype (historical annualized bleeding rate [ABR] >5 bleeds/year before regular FVIII prophylaxis) who received low-/intermediate-dose FVIII secondary prophylaxis ≥8 months were enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!